Hong Kong Pharma Digital Technology Holdings Limited (HKPD) AI Stock Analysis
HKPD AI stock analysis summary
AI ResearchHong Kong Pharma Digital Technology Holdings Limited (HKPD), now named Cellyan Biotechnology Co., Ltd, provides OTC pharmaceutical cross-border supply chain and distribution services in Hong Kong and Mainland China. In FY2026, revenue dropped 33.9% to $13.4M while net income fell to -$1.1M. Over the trailing twelve months, the company posted an operating margin of -19.3% and held $221,841 in cash.
- Market cap
- $5.4M
- Revenue (TTM)
- $13.4M
- P/E
- —
- 1Y return
- -90.8% S&P 500 16.8%
- Avg. target
- —
Bull case
- The stock trades at a price-to-book ratio of 0.6x and a price-to-sales ratio of 0.4x.
- The balance sheet maintains a current ratio of 3.86 as of June 30, 2026.
- Capital expenditures remained low at $35,470 for FY2026.
Bear case
- Revenue fell 33.9% in FY2026 to $13.4M while net income dropped to -$1.1M.
- Free cash flow was negative at -$787,072 in FY2026, leaving $221,841 in cash and short-term investments as of June 30, 2026.
- Operating margin deteriorated to -19.3% for the trailing twelve months, well below the 14.0% median of its US-listed Healthcare peers.
What Hong Kong Pharma Digital Technology does
Cellyan Biotechnology Co., Ltd, formerly known as Hong Kong Pharma Digital Technology Holdings Limited, is an investment holding company engaged in the over-the-counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides cross-border procurement, distribution, and e-commerce supply chain services for OTC pharmaceuticals. Its logistics operations include customs clearance, drugs enlisting, and warehousing. It also provides value-added services such as labeling, extended storage, product inspection, batch processing, logistics support, and sales of health supplements and non-pharmaceutical products to e-commerce logistics partners, merchants, Chinese e-commerce platforms, and pharmaceutical distributors.
Growth and profitability
Revenue rose from $12.6M in FY2023 to $16.7M in FY2024 and reached $20.3M in FY2025, before declining 33.9% to $13.4M in FY2026. This produced a 3-year revenue CAGR of 2.3% from FY2023 to FY2026. Gross margin declined from 21.8% in FY2023 to 10.3% in FY2026. Net income turned negative, moving from $1.3M in FY2024 to -$27,056 in FY2025 and -$1.1M in FY2026. For the trailing twelve months ending June 30, 2026, revenue was $13.4M with an operating margin of -19.3% and EPS of -$0.07. In the latest quarter, revenue declined 31.7% year-over-year and earnings declined 83.1%.
Balance sheet and cash flow
As of June 30, 2026, cash and short-term investments stood at $221,841 against total debt of $1.3M, leaving net debt at $1.0M. Total assets were $12.8M and shareholders' equity was $9.6M. Liquidity showed a current ratio of 3.86 and a debt-to-equity ratio of 0.13. In FY2026, operating cash flow was -$751,602 and free cash flow was -$787,072, with capital expenditures totaling $35,470.
Valuation and performance
HKPD carries a market cap of $5.4M and an enterprise value of $6.8M. It trades at a price-to-sales multiple of 0.4x, below the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio is 0.6x. The company trades at an EV/EBITDA multiple of 21.9x, compared to the peer median of 12.0x, and an EV/revenue of 0.5x. Over the past year, HKPD fell 90.8%, compared to a 16.8% gain for the S&P 500 (SPY), and closed at $0.11 on October 16, 2026, which is 78.1% below its 200-day average.
What analysts expect
No analyst ratings, price targets, earnings track record, or upcoming earnings dates are listed for HKPD. Insider ownership represents 17.0% of shares, institutional ownership stands at 0.6%, and short interest accounts for 0.2% of the float. The stock's last close was $0.11 on October 16, 2026, near its 52-week low of $0.10 and below its 52-week high of $1.72.
Key risks and what to watch
- Cash and short-term investments stood at $221,841 on June 30, 2026, following -$751,602 in FY2026 operating cash flow.
- Quarterly revenue fell 31.7% year-over-year in the period ending June 30, 2026.
- Gross margin compressed from 21.8% in FY2023 to 10.3% in FY2026.
- The stock has dropped 90.8% over the past year and trades 78.1% below its 200-day average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this HKPD AI stock analysis
This page is an AI-written research summary of Hong Kong Pharma Digital Technology Holdings Limited (HKPD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: HKPD income statement, HKPD balance sheet, HKPD key metrics, HKPD chart. See the HKPD stock overview for the latest quote and news.
HKPD AI stock analysis FAQ
What does HKPD do?
The company, operating as Cellyan Biotechnology Co., Ltd, provides OTC pharmaceutical cross-border procurement, distribution, and e-commerce supply chain logistics in Hong Kong and Mainland China.
What was HKPD's revenue in FY2026?
HKPD generated $13.4M in revenue in FY2026, down 33.9% from $20.3M in FY2025.
Does HKPD pay a dividend?
HKPD does not report any dividend payments.
How much debt does HKPD have?
As of June 30, 2026, HKPD had total debt of $1.3M and cash of $221,841, resulting in net debt of $1.0M.
Who owns HKPD stock?
Insiders hold 17.0% of the stock, institutional investors hold 0.6%, and short interest is 0.2% of the float.